Mary DiBiase
2022
In 2022, Mary DiBiase earned a total compensation of $1.8M as Chief Operating Officer at X4 Pharmaceuticals.
Compensation breakdown
| Bonus | $42,793 |
|---|---|
| Non-Equity Incentive Plan | $179,730 |
| Option Awards | $954,900 |
| Salary | $426,296 |
| Stock Awards | $226,800 |
| Other | $12,769 |
| Total | $1,843,288 |
DiBiase received $954.9K in option awards, accounting for 52% of the total pay in 2022.
DiBiase also received $42.8K in bonus, $179.7K in non-equity incentive plan, $426.3K in salary, $226.8K in stock awards and $12.8K in other compensation.
Rankings
In 2022, Mary DiBiase's compensation ranked 1,886th out of 5,717 executives tracked by ExecPay. In other words, DiBiase earned more than 67.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,886 out of 5,717 | 67th |
Division Manufacturing | 995 out of 3,111 | 68th |
Major group Chemicals And Allied Products | 413 out of 1,410 | 71st |
Industry group Drugs | 378 out of 1,311 | 71st |
Industry Biological Products, Except Diagnostic Substances | 96 out of 291 | 67th |
Source: SEC filing on April 25, 2023.
DiBiase's colleagues
We found two more compensation records of executives who worked with Mary DiBiase at X4 Pharmaceuticals in 2022.